COMMUNIQUÉS West-GlobeNewswire

ICU Medical Announces Fourth Quarter 2023 Results and Provides Fiscal Year 2024 Guidance
27/02/2024
SAN CLEMENTE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the [...]
OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results
27/02/2024
Conference call begins at 4:30 p.m. Eastern time today MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended [...]
RadNet to Enter the Houston, Texas Market through Platform Acquisition of Houston Medical Imaging
27/02/2024
LOS ANGELES, Feb. 27, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announces that it has signed a [...]
OraSure Reports Q4 ‘23 Revenue of $75.9 Million
27/02/2024
Q4 GAAP EPS of $0.27 ; Q4 Non-GAAP EPS of $0.22 Grew cash balance to $290.4 million as of December 31, 2023 E nters U.S. Syphilis testing market via strategic distribution agreement with Diagnostics Direct BETHLEHEM, Pa [...]
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results
27/02/2024
Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Enrollment continues in BEACON-IPF, a Phase 2b trial in patients with IPF SOUTH SAN FRANCISCO, Calif., Feb [...]
PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2023 Results
27/02/2024
SAN JOSE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics ® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions [...]
Progyny, Inc. Announces Fourth Quarter 2023 Results
27/02/2024
Reports Record Full Year Revenue of $1,088.6 Million, Reflecting 38% Growth Achieves 49% Growth in Adjusted EBITDA to Record $187.1 Million Issues Financial Guidance for 2024, Crossing the $1.3 Billion Milestone at [...]
Anika to Issue Fourth Quarter and Year-End 2023 Financial Results on Wednesday, March 13, 2024
27/02/2024
BEDFORD, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its [...]
Ventyx Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Corporate Progress
27/02/2024
Ventyx to host virtual investor event on March 11 th to provide clinical updates on our NLRP3 portfolio and from the open-label extension of the VTX002 Phase 2 trial in ulcerative colitis Cash, cash equivalents and [...]
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
27/02/2024
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in KOMET-008 trial of ziftomenib [...]
Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
27/02/2024
-- VAX-31 Adult Program Phase 1/2 Study Enrollment Complete; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Completed Successful VAX-24 Phase 2 Adult Program and End-of- [...]
Alignment Healthcare Reports Fourth Quarter and Full-Year 2023 Results; Provides Full-Year 2024 Financial Guidance
27/02/2024
Reports $1.82 billion in total revenue for full-year 2023 and 119,200 health plan members at year end, up 27.2% and 21.1% year-over-year respectively Records strong health plan membership growth after annual enrollment [...]
Cytokinetics Reports Fourth Quarter 2023 Financial Results
27/02/2024
Topline Results from SEQUOIA-HCM Announced in December Showed Statistically Significant and Clinically Meaningful Increase in Primary Efficacy Endpoint and Improvements in All Secondary Endpoints Company Plans to Submit [...]
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update
27/02/2024
Conference Call to Begin Today at 5:00 p.m. (ET) 2023 Total revenues of $199M; +99% vs. 2022 4Q 2023 Total revenues of $58M; +62% vs. 2022 4Q 2023 Net income of $1M; Non-GAAP net income of $7M $302M of cash and cash [...]
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
27/02/2024
Large phase 2 global study will evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Feb. 27, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a [...]
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
27/02/2024
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document [...]
Capital Increase in Genmab as a Result of Employee Warrant Exercise
27/02/2024
Company Announcement COPENHAGEN, Denmark; February 27, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 48,429 shares as a consequence of the exercise of employee warrants. The increase is effected [...]
Aclarion Announces Closing of $3.0 Million Public Offering
27/02/2024
BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW) , a healthcare technology company that is leveraging biomarkers and proprietary [...]
Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
27/02/2024
BETHESDA, Md., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]

Pages